ArticlePharmaceutics2019
Influenza Virus-Like Particles Presenting both
Article in Pharmaceutics, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Vaccinia virus expressing MIC8 and AMA1 provides protection against Toxoplasma gondii ME49 infection.Parasites, hosts and diseases · 2025Article
- Influenza virus-like particles presentingNanomedicine (London, England) · 2025Article
- Enhanced Vaccine Design Strategies for Toxoplasmosis: A Computational Analysis ofArchives of Razi Institute · 2025Article
- Efficacy of Heterologous Vaccination Using Virus-Like Particles and Vaccinia Virus Containing MIC8 and AMA1 Proteins ofVaccines · 2025Article
- Protective Efficacy Induced by Virus-like Particles Expressing Dense Granule Protein 5 ofVaccines · 2025Article
- PLGA nanoparticles as an efficient carrier inFrontiers in immunology · 2025Article
- Toxoplasma rhoptry proteins that affect encephalitis outcome.Cell death discovery · 2023Review
- The detection of Toxoplasma gondii ME49 infections in BALB/c mice using various techniques.Parasites, hosts and diseases · 2023Article
- Recent progress in vaccine development targeting pre-clinical human toxoplasmosis.Parasites, hosts and diseases · 2023Article
- Nanoparticles as a Delivery System of Antigens for the Development of an Effective Vaccine againstVaccines · 2023Review
- Synthetic selenium nanoparticles as co-adjuvant improved immune responses against methicillin-resistant Staphylococcus aureus.World journal of microbiology & biotechnology · 2022Article
- Protection Induced by Vaccination with Recombinant Baculovirus and Virus-like Particles ExpressingVaccines · 2022Article
- Orally Administrated Recombinant Vaccinia Virus Displaying ROP4 Induces Protection againstVaccines · 2022Article
- Detection of Toxoplasma gondii Infections using Virus-Like Particles Displaying T. gondii ROP4 Antigen.The Korean journal of parasitology · 2021Article
- Passive Immunity and Antibody Response Induced byVaccines · 2021Article
- Advances inVaccines · 2021Review
- Mucosal Administration of Recombinant Baculovirus DisplayingFrontiers in cellular and infection microbiology · 2021Article
- Evaluation of CpG-ODN-AdjuvantedPharmaceutics · 2020Article
- Nanoparticles to Improve the Efficacy of Vaccines.Pharmaceutics · 2020Article
- Study on Circulating Antigens in Serum of Mice With Experimental Acute Toxoplasmosis.Frontiers in microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Rhoptry organelle proteins (ROPs) secreted by
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.